<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214096</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-01-302</org_study_id>
    <nct_id>NCT01214096</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind , Placebo Parallel Controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zensun Sci. &amp; Tech. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zensun Sci. &amp; Tech. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous
      Administration in Patients With Chronic Systolic Heart Failure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Subcutaneous Administration of NRG-1 is well tolerated by CHF patients

        2. Subcutaneous Administration of NRG-1 improves the cardiac function of CHF patients

        3. Assessment of relative bioavailability of NRG-1 by Subcutaneous Administration
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The same protocol has been launched in United States.
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac function measured by MRI</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac function</measure>
    <time_frame>baseline, 30 days, 90day and180 days</time_frame>
    <description>6-minute walk test, cardiac function classification(NYHA)，life quality score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNRG-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant human neuregulin-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNRG-1</intervention_name>
    <description>Subcutaneous Administration:0.6ug/kg/day for 10days</description>
    <arm_group_label>rhNRG-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNRG-1</intervention_name>
    <description>Subcutaneous Administration 1.2ug/kg/day for 10 days</description>
    <arm_group_label>rhNRG-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNRG-1</intervention_name>
    <description>Vein infusion:0.6ug/kg/day for 10 days</description>
    <arm_group_label>rhNRG-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-75 years old, no limitation in gender;

          2. Left ventricular ejection fraction (LVEF) ≤ 40% (ECHO);

          3. Patients with chronic heart failure (NYHA class II or III);

          4. In the past one month, the clinical condition (including history, clinical symptoms
             and signs) was relatively stable;

          5. Patients on standard treatment of chronic heart failure at the target dose or maximum
             tolerance dose for over 1 month ,or unchanged dose in last 1 month;

          6. Understand and sign the informed consent form;

        Exclusion Criteria:

          1. Atrial fibrillation;

          2. Subject underwent cardiac pacemaker treatment;

          3. Subject underwent metal graft treatment;

          4. Claustrophobia;

          5. Acute myocardial infarction, cardiac ischemia indicated by 6-minute walk test,
             hypertrophic cardiomyopathy, constrictive pericarditis, significant valve disease or
             congenital heart disease, severe pulmonary hypertension;

          6. Ischemic heart failure without the revascularization or undergone the
             revascularization within last 6 months;

          7. Subject underwent cardiac surgery or cerebrovascular events within the previous six
             months;

          8. Subjects who plan to have cardiac transplantation;

          9. Severe hepatic and renal insufficiency (serum creatinine&gt;2.0 mg /dl, AST or ALT is
             five times higher than the upper limit of normal range);

         10. Subject needs mechanical ventilation;

         11. Systolic blood pressure &lt; 90mmHg, or &gt; 160mmHg;

         12. Chronic heart failure complicated with acute hemodynamic disturbance or acute
             decompensation within last 1 month;

         13. Mobitz Type II or III° atrial ventricular block，severe ventricular arrhythmia
             (polymorphic and frequent premature ventricular beats, frequent non-sustained
             ventricular tachycardia);

         14. Serum potassium&lt;3.2mmol/L, or&gt;5.5mmol/L;

         15. Female subject is pregnant or plan to become pregnant

         16. Childbearing-aged female subject who is unmarried or dose not bear child;

         17. Subject with life expectancy less than 6 months as assessed by investigators;

         18. Subject participated in any other clinical trial within the previous three months;

         19. Subject with previous history of tumor, or current tumor patient, or subject with
             pre-cancerous disease manifested by pathological examination (such as ductal carcinoma
             in situ or cervical epithelial dysplasia)

         20. Examinations (physical examination, X-ray examination, type-B ultrasonic detection or
             other methods) reveal that the subject has malignant mass, gland hyperplasia or
             adenoma with endocrine activity, or impact on heart, or endocrine function (such as
             pheochromocytoma, thyroid enlargement);

         21. The Investigator deemed for whatever reason that the subject is not likely to complete
             the study or comply with the study procedures (due to administration or any other
             reason).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital of Capital University of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute &amp; Fuwai Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Heart failure</keyword>
  <keyword>rhNRG-1</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

